Publications by authors named "Ioannis Kouverianos"
Is there a Role for Anti-IL-5 Therapies in Eosinophilic Fasciitis?
Mediterr J Rheumatol
December 2023
Article Synopsis
- Eosinophilic Fasciitis (EF) is a rare disease characterized by swelling in the subcutaneous fascia and muscle, primarily affecting the upper arms and thighs, with no standard treatment available.
- A review of studies focused on anti-Interleukin-5 (IL-5) therapies found only one case where reslizumab, an anti-IL-5 therapy, successfully treated a patient whose symptoms were not controlled by standard immunosuppressive treatments.
- The exact cause of EF is still unknown, and while traditional treatments like corticosteroids are often ineffective and have side effects, targeting eosinophils with IL-5 therapies may offer a promising alternative approach.
Eosinophilic granulomatosis with polyangiitis (EGPA) is an antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, mostly affecting small-sized arteries and usually occurring in patients with an allergic background. Eosinophils seem to play a significant role in the pathogenesis of the disease and, therefore, biologics targeting interleukin 5 (IL5), a cytokine tightly linked to eosinophils, have emerged as a promising therapeutic tool. A systematic review of Medline was conducted from 2007 to 2022 to search for data regarding the use of anti-IL5 therapies in patients with EGPA.
View Article and Find Full Text PDF